Dimethyl fumarate–associated transient bone marrow oedema syndrome

Abstract

Background:

Dimethyl fumarate (DMF) is a commonly used and effective treatment for relapsing and remitting multiple sclerosis. Its use results in impairment of the transcription factor nuclear factor erythroid-derived 2 (E2)-related factor (Nrf2), which is involved in both immunomodulation and bone health. DMF has not previously been reported to cause bone marrow complications, though other fumarates including tenofovir have. The mechanism of fumarate-associated bone toxicity remains unclear with altered osteoblastic gene expression and function suggested.

Methods:

We present a case of a 54-year-old female with relapsing remitting multiple sclerosis (RRMS) treated for 30 months with DMF who developed relapsing atraumatic lower limb bone pain.

Results:

Serial imaging revealed multifocal areas of bone marrow oedema and trabecular fractures. The patient was diagnosed with transient bone marrow oedema syndrome. Management consisted of cessation of therapy and treatment with the pro-osteobalstic agent denosumab.

Conclusion:

In this instance of DMF-associated bone marrow oedema, cessation of DMF and treatment with denosumab resulted in symptomatic improvement. DMF therapy may potentially result in bone marrow oedema due to inhibition of common upstream signalling pathways, including the Nrf2 signalling pathway.

Keywords

Dimethyl fumarate multiple sclerosis bone marrow oedema

Get full access to this article

View all access options for this article.

References

Linker

Haghikia

Dimethyl fumarate in multiple sclerosis: Latest developments, evidence and place in therapy. Ther Adv Chronic Dis 2016; 7: 198–207.

Patel

Primary bone marrow oedema syndromes. Rheumatology 2014; 53(5): 785–792.

Vera

Walker

Kinderlerer

et al . Transient bone marrow oedema syndrome in an HIV-infected patient on highly active antiretroviral therapy. Int J STD AIDS 2012; 23: 213–215.

Radmer

Andresen

Recurrent bone marrow oedemas and insufficiency fractures in HIV patients on antiviral therapy. Calcif Tissue Int 2017; 100(5 Suppl. 1): 132.

Starr

Wessely

Albastaki

et al . Bone marrow edema: Pathophysiology, differential diagnosis, and imaging. Acta Radiol 2008; 49(7): 771–786.

Gill

Zissimopoulos

Al-Shamma et al . Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: Can the fracture risk assessment tool identify those at greatest risk? J Infect Dis 2015; 211: 374–382.

Grigsby

Pham

Mansky

et al . Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 6: 41–47.

Zhao

Liu

Fang

et al . Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α). Biochem Biophys Res Commun 2014; 448(3): 303–307.

Rolvien

Schmidt

Butscheidt

et al . Denosumab is effective in the treatment of bone marrow oedema syndrome. Injury 2017; 48(4): 874–879.